Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, phase II study to assess the efficacy, safety, and tolerability of
Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF),
post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior
treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor
(JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three
times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6,
patients may continue receiving reparixin once daily on a 4-week cycle if at least stable
disease (SD) is met by IWG-MRT criteria until loss of response, disease progression,
unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.